

Corrado CaracÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6141538/publications.pdf>

Version: 2024-02-01

54
papers

2,653
citations

201674

27
h-index

182427

51
g-index

59
all docs

59
docs citations

59
times ranked

4424
citing authors

#	ARTICLE	IF	CITATIONS
1	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 200.	4.4	0
2	The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. <i>BMC Cancer</i> , 2021, 21, 8.	2.6	2
3	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2430.	2.4	10
4	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019,) <i>TJ ETQq, 0, 0 rgBT /Overlock</i>	4.4	5
5	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	2.6	24
6	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	4.4	24
7	Prognostic impact of regression in patients with primary cutaneous melanoma >1Âmm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	1.2	19
8	Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 271-279.	1.5	44
9	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1405206.	4.6	43
10	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	4.4	85
11	Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. <i>Journal of Translational Medicine</i> , 2017, 15, 82.	4.4	35
12	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.	0.7	13
13	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>Journal of Translational Medicine</i> , 2015, 13, 37.	4.4	15
14	Clinicopathologic features and surgical management of primary umbilical melanoma: a case series. <i>BMC Research Notes</i> , 2015, 8, 147.	1.4	5
15	Vemurafenib beyond progression in a patient with metastatic melanoma. <i>Anti-Cancer Drugs</i> , 2015, 26, 464-468.	1.4	2
16	Electrochemotherapy in melanoma patients: a single institution experience. <i>Melanoma Management</i> , 2015, 2, 127-132.	0.5	7
17	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008842.	4.6	72
18	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	4.6	318

#	ARTICLE	IF	CITATIONS
19	Number of Excised Lymph Nodes as a Quality Assurance Measure for Lymphadenectomy in Melanoma. <i>JAMA Surgery</i> , 2014, 149, 700.	4.3	42
20	Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 935-941.	1.6	49
21	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
22	Surgical Management of Sentinel Lymph Node Biopsy Outside Major Nodal Basin in Patients with Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 300-305.	1.5	12
23	Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma. <i>Journal of Translational Medicine</i> , 2014, 12, P1.	4.4	0
24	Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. <i>World Journal of Surgical Oncology</i> , 2013, 11, 36.	1.9	18
25	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- γ in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	4.4	21
26	Sentinel Node Biopsy in Thin and Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2780-2786.	1.5	72
27	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	4.4	31
28	Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. <i>BMC Cancer</i> , 2013, 13, 564.	2.6	53
29	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	1.6	419
30	Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. <i>World Journal of Surgical Oncology</i> , 2012, 10, 275.	1.9	42
31	Half forehead reconstruction with a single rotational scalp flap for dermatofibrosarcoma protuberans treatment. <i>World Journal of Surgical Oncology</i> , 2012, 10, 78.	1.9	3
32	Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 131.	4.4	30
33	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8573-8573.	1.6	13
34	Previously Reported Sonographic Appearances of Regional Melanoma Metastases Are Not Likely Due to Necrosis. <i>Journal of Ultrasound in Medicine</i> , 2011, 30, 1041-1049.	1.7	23
35	Metastatic eccrine porocarcinoma: report of a case and review of the literature. <i>World Journal of Surgical Oncology</i> , 2011, 9, 32.	1.9	63
36	The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatology</i> , 2010, 10, 5.	2.1	13

#	ARTICLE	IF	CITATIONS
37	Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. <i>Cancer Biology and Therapy</i> , 2010, 9, 423-429.	3.4	30
38	Locoregional Spread of Cutaneous Melanoma: Sonography Findings. <i>American Journal of Roentgenology</i> , 2010, 194, 735-745.	2.2	58
39	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon- β 2b treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 76.	4.4	39
40	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009, 9, 352.	2.6	42
41	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1713-1742.	6.4	159
42	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>European Journal of Cancer</i> , 2007, 43, 137-143.	2.8	28
43	Laparoscopic cholecystectomy for melanoma metastatic to the gallbladder: is it an adequate surgical procedure? Report of a case and review of the literature. <i>World Journal of Surgical Oncology</i> , 2007, 5, 141.	1.9	37
44	Resection in the popliteal fossa for metastatic melanoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 8.	1.9	11
45	Soluble interleukin-2 receptor in stage III melanoma. <i>Cytokine</i> , 2006, 33, 150-155.	3.2	24
46	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> , 2006, 6, 266.	2.6	19
47	Human Melanoma Metastases Express Functional CXCR4. <i>Clinical Cancer Research</i> , 2006, 12, 2427-2433.	7.0	114
48	Renal cell carcinoma with solitary toe metastasis. <i>International Journal of Urology</i> , 2005, 12, 401-404.	1.0	33
49	Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal De Meleda). <i>Journal of Surgical Oncology</i> , 2003, 84, 229-233.	1.7	24
50	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
51	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. <i>International Journal of Oncology</i> , 2003, 22, 1209-15.	3.3	5
52	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Clinical Oncology</i> , 2001, 19, 1437-1443.	1.6	63
53	Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001, 11, 83-84.	1.2	1
54	Intermediate dose recombinant interferon- γ as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. <i>Cancer</i> , 2000, 89, 1490-1494.	4.1	9